Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day.
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and crypto all at once.
KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.
Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript
PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day.
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and crypto all at once.
KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.
Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript
Krystal Biotech NASDAQ: KRYS reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overseas.
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.29 per share a year ago.
$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance sheet, ending the quarter with $1.1 billion in cash and investments PITTSBURGH, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company” or “Krystal”) (NASDAQ: KRYS) today reported financial results for the second quarter ended June 30, 2026 and provided a business update. “Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a pipeline now moving toward multiple registrational readouts,” said Krish S.
Krystal Biotech (KRYS) earns a STRONG BUY rating, driven by its fortress-like balance sheet, exceptional margins, and rapid Vyjuvek commercial success. KRYS's international Vyjuvek launches in Europe and Japan are accelerating topline growth, with further expansion into Italy, Spain, and the UK expected to boost revenues. KRYS's pipeline, leveraging its proprietary HSV-1 platform, spans respiratory, ophthalmology, oncology, and aesthetics, reducing future reliance on Vyjuvek.
Krystal Biotech remains a Buy as VYJUVEK drives profitability and its HSV-1 platform underpins a robust pipeline. Q1 results highlight operating leverage: $116.4M VYJUVEK revenue, $56M net income, and self-funded R&D with a $1B cash position. Upcoming catalysts include registrational data for KB803 and KB801, with KB801 positioned as a potential blockbuster in rare ophthalmology.
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assetmark Inc. bought a new position in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 3,157 shares of the company's stock, valued at approximately $816,000. A number of other institutional
Krystal Biotech is posting strong sales thanks to a breakthrough in an underserved therapeutic area. Exelixis has carved out a niche in the cancer-drug market, which much larger companies typically dominate.
Fifth Third Bancorp boosted its stake in Krystal Biotech, Inc. (NASDAQ: KRYS) by 3,958.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,925 shares of the company's stock after acquiring an additional 5,779 shares during the quarter. Fifth
PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 2026, prior to the open of U.S. markets.
NEW YORK, July 20, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600
The sky is the limit for these companies.
Krystal Biotech (KRYS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
Moderna is racing towards important clinical and regulatory catalysts. Krystal Biotech still has a large market to address in its core area.
Investors need to pay close attention to KRYS stock based on the movements in the options market lately.
KRYS shares climb 16% in three months as Vyjuvek revenues jump 32%, pipeline programs advance and a nearly $1B cash pile fuels confidence.
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
